What it is used for

DANTRIUM is indicated in controlling the manifestations of clinical spasticity resulting from serious chronic disorders such as spinal cord injury, stroke, cerebral palsy, or multiple sclerosis. It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. There is no evidence that patients with contractures will benefit. DANTRIUM is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders or electroconvulsive therapy. If improvement occurs, it will ordinarily occur within the dosage titration schedule (see DOSAGE AND ADMINISTRATION), as manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without DANTRIUM. Occasionally, subtle but meaningful improvements in spasticity may occur with DANTRIUM therapy. In such instances information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of DANTRIUM for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestation of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of DANTRIUM on a long term basis is justified if introduction of the drug into the patient's regimen produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of an annoying manifestation of spasticity considered important by the patient himself.

How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

• Store below 30 degrees Celsius
• Shelf lifetime is 36 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Visual appearance

Capsule: No. 3 hard gelatin capsule with a tan opaque body and orange opaque cap. Capsules are imprinted with "Dantrium" "25 mg" on the cap and "0149" "0030" and single coding bars on the body in black ink. Fill: deep orange cylindrical plug.

Images are the copyright of the Pharmacy Guild of Australia

Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine. open tool tip to find out more

Is this medicine subsidised?

This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.

Pregnant or planning a pregnancy?

For the active ingredient dantrolene

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

What it is used for

DANTRIUM is indicated in controlling the manifestations of clinical spasticity resulting from serious chronic disorders such as spinal cord injury, stroke, cerebral palsy, or multiple sclerosis. It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. There is no evidence that patients with contractures will benefit. DANTRIUM is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders or electroconvulsive therapy. If improvement occurs, it will ordinarily occur within the dosage titration schedule (see DOSAGE AND ADMINISTRATION), as manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without DANTRIUM. Occasionally, subtle but meaningful improvements in spasticity may occur with DANTRIUM therapy. In such instances information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of DANTRIUM for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestation of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of DANTRIUM on a long term basis is justified if introduction of the drug into the patient's regimen produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of an annoying manifestation of spasticity considered important by the patient himself.

How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

• Store below 30 degrees Celsius
• Shelf lifetime is 3 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Visual appearance

Capsule:No.2 hard gelatin capsule with a tan opaque body and orange opaque cap, imprinted with the logo "Dantrium" "50mg" on the cap and "0149" "0031" and single coding bars on the body in black ink. Fill: deep orange cylindrical plug.

Images are the copyright of the Pharmacy Guild of Australia

Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine. open tool tip to find out more

Pregnant or planning a pregnancy?

For the active ingredient dantrolene

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.